

2020 Webinar Series

“CIOMS consensus report on Drug-Induced Liver Injury (DILI)”

7pm* to 8.30pm (Singapore Time), 20th July 2020 via Zoom

*Corresponds to 7am Eastern Standard Time (EST), 1pm Central European Time (CET) & 9pm Australian Central Standard Time (ACT)

Time	Programme	Speakers
7.00pm	Welcome	Professor Hervé Le Louët President Council for International Organizations of Medical Sciences (CIOMS) Head, Vigilance Department Hôpital Universitaire Henri Mondor AP-HP Paris Créteil, France
	Introduction of Speakers Report of CIOMS DILI Working Group	Professor Mark I Avigan Associate Director Critical Path Initiatives Office of Pharmacovigilance & Epidemiology Center for Drug Evaluation & Research U.S. Food and Drug Administration (USFDA)
	What CIOMS Is And What It Does : The DILI Initiative	Professor Hervé Le Louët CIOMS
	Principles in Detection, Characterization and Risk Assessment of DILI in Clinical Trials	Dr Arie Regev Chair, Liver and GI Safety Committee Chair, Safety Advisory Hub Global Patient Safety Eli Lilly and Company
	Liver Safety Biomarkers and Herbal and Dietary Supplement Hepatotoxicity	Professor Raul J Andrade Head, Department of Medicine University of Málaga Chief, Gastroenterology Service Virgen de la Victoria University Hospital Málaga (Spain)
	Best practices in post-market DILI risk assessment, risk minimization and communication	Dr Walter Straus Associate Vice-President and Chair Organ-Specific Safety Boards Clinical Safety & Risk Management Merck Research Laboratories Merck & Co., Inc The United States of America
	Questions	Professor Einar S Björnsson Chief of Internal Medicine National University Hospital of Iceland Reykjavik (Iceland)

	<p>Panel Session and Q&A</p>	<p><u>Moderator:</u> Professor Mark I Avigan USFDA</p> <p><u>Panellists:</u> Professor Hervé Le Louët Council for International Organizations of Medical Sciences (CIOMS)</p> <p>Dr Arie Regev Eli Lilly and Company</p> <p>Professor Raúl J Andrade University of Málaga</p> <p>Professor Einar Stefán Björnsson Landspítali University Hospital Reykjavik (Iceland)</p>
	<p>Summary and Key Takeaways</p>	<p>Professor Mark I Avigan USFDA</p>
	<p>Closing Remarks</p>	<p>Professor Hervé Le Louët CIOMS</p>
<p>8.30pm</p>	<p>End of Webinar</p>	